Great Lakes Advisors LLC Has $2.35 Million Stock Holdings in Enovis Co. (NYSE:ENOV)

Great Lakes Advisors LLC increased its position in shares of Enovis Co. (NYSE:ENOV) by 4.7% during the 4th quarter, HoldingsChannel reports. The fund owned 53,584 shares of the company’s stock after purchasing an additional 2,415 shares during the quarter. Great Lakes Advisors LLC’s holdings in Enovis were worth $2,351,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. UMB Bank n.a. lifted its stake in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the period. Pinnacle Bancorp Inc. lifted its stake in shares of Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after acquiring an additional 300 shares during the period. FMR LLC lifted its stake in shares of Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after acquiring an additional 484 shares during the period. XTX Topco Ltd acquired a new position in shares of Enovis during the third quarter valued at $217,000. Finally, Legacy Capital Wealth Partners LLC acquired a new position in shares of Enovis during the fourth quarter valued at $228,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC dropped their price objective on Enovis from $65.00 to $64.00 and set a “buy” rating for the company in a report on Thursday, February 27th.

Enovis Trading Up 3.4 %

NYSE ENOV opened at $37.01 on Friday. The stock has a 50-day simple moving average of $43.32 and a 200 day simple moving average of $43.73. The company has a market capitalization of $2.11 billion, a PE ratio of -16.90 and a beta of 2.05. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12 month low of $35.14 and a 12 month high of $62.79.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.06. The business had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Research analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.